Responses
Helicobacter pylori
Original article
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Compose a Response to This Article
Other responses
No responses have been published for this article.